![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Forder, A Scriabine and H Rasmussen
Isolated perfused rabbit ear arteries contract when treated with 12-O- tetradecanoylphorbol-13-acetate (TPA), an activator of the calcium- activated, phospholipid-dependent protein kinase or C-kinase. Under conditions where the calcium concentration in the perfusate is 1.5 mM and the potassium concentration is 4.8 mM, there is a latent period of 70 +/- 19 min (mean +/- S.E.M., n = 10) between TPA addition and the onset of the contractile response. Once initiated, the contractile response is progressive and sustained. When perfusion conditions are altered in such a way as to modify calcium flux across the plasma membrane (i.e., raising the extracellular calcium concentration to 2.5 mM Ca++, raising the extracellular potassium concentration to 10 mM, and/or preincubating the tissues in media containing 100 nM Bay K 8644, a potent calcium channel agonist), the latency period between TPA addition and initiation of the contractile response is significantly reduced (2.5 mM Ca++, 37 +/- 7 min; 10 mM K+ and 2.5 mM Ca++, 11 +/- 3 min; 100 nM Bay K 8644 and 1.5 mM Ca++, 20 +/- 7 min; 100 nM Bay K 8644 and 2.5 mM Ca2+, 8.5 +/- 1.7 min; 10 mM K+ and 100 nM Bay K 8644, 11 +/- 5 min). Likewise, the combination of 2.5 mM calcium, 100 nM Bay K 8644, and 3.3 microM ouabain results in a contractile response 4.5 +/- 2.0 min after TPA addition (means +/- S.E.M., n = 4). Control tissues (absence of TPA addition) run simultaneously show no contractile responses to the various Ca++ flux regulators even after 90 min of incubation.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  H Reynaert, M G Thompson, T Thomas, and A Geerts Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension Gut, April 1, 2002; 50(4): 571 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Barman Effect of protein kinase C inhibition on hypoxic pulmonary vasoconstriction Am J Physiol Lung Cell Mol Physiol, May 1, 2001; 280(5): L888 - L895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Akimoto, E. Kusano, N. Fujita, K. Okada, O. Saito, S. Ono, Y. Ando, S. Homma, T. Saito, and Y. Asano Erythropoietin modulates angiotensin II- or noradrenaline-induced Ca2+ mobilization in cultured rat vascular smooth-muscle cells Nephrol. Dial. Transplant., March 1, 2001; 16(3): 491 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Longo, Y. Zhao, W. Long, C. Miguel, R. S. Windemuth, A.-M. Cantwell, A. T. Nanyonga, T. Saito, and L. Zhang Dual role of PKC in modulating pharmacomechanical coupling in fetal and adult cerebral arteries Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2000; 279(4): R1419 - R1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Kim, T. Saunders, E. Bieber, and M. Phillippe Tissue-Specific Protein Kinase C Isoform Expression in Rat Uterine Tissue Reproductive Sciences, November 1, 1999; 6(6): 293 - 300. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Barman Potassium channels modulate canine pulmonary vasoreactivity to protein kinase C activation Am J Physiol Lung Cell Mol Physiol, September 1, 1999; 277(3): L558 - L565. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
